AU2016340264B2 - 2,4-dihydroxy-nicotinamides as APJ agonists - Google Patents
2,4-dihydroxy-nicotinamides as APJ agonists Download PDFInfo
- Publication number
- AU2016340264B2 AU2016340264B2 AU2016340264A AU2016340264A AU2016340264B2 AU 2016340264 B2 AU2016340264 B2 AU 2016340264B2 AU 2016340264 A AU2016340264 A AU 2016340264A AU 2016340264 A AU2016340264 A AU 2016340264A AU 2016340264 B2 AU2016340264 B2 AU 2016340264B2
- Authority
- AU
- Australia
- Prior art keywords
- carbonyl
- dimethoxyphenyl
- pyridine
- butyl
- diol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562241367P | 2015-10-14 | 2015-10-14 | |
| US62/241,367 | 2015-10-14 | ||
| US201562270659P | 2015-12-22 | 2015-12-22 | |
| US62/270,659 | 2015-12-22 | ||
| PCT/US2016/056769 WO2017066402A1 (en) | 2015-10-14 | 2016-10-13 | 2,4-dihydroxy-nicotinamides as apj agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2016340264A1 AU2016340264A1 (en) | 2018-05-31 |
| AU2016340264B2 true AU2016340264B2 (en) | 2021-01-07 |
Family
ID=57178558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016340264A Ceased AU2016340264B2 (en) | 2015-10-14 | 2016-10-13 | 2,4-dihydroxy-nicotinamides as APJ agonists |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10392347B2 (en:Method) |
| EP (1) | EP3362442B1 (en:Method) |
| JP (1) | JP6837482B2 (en:Method) |
| KR (1) | KR102707502B1 (en:Method) |
| CN (1) | CN108368087B (en:Method) |
| AU (1) | AU2016340264B2 (en:Method) |
| BR (1) | BR112018007395A2 (en:Method) |
| CA (1) | CA3001974A1 (en:Method) |
| CL (1) | CL2018000953A1 (en:Method) |
| CO (1) | CO2018004968A2 (en:Method) |
| EA (1) | EA034857B1 (en:Method) |
| ES (1) | ES2774945T3 (en:Method) |
| IL (1) | IL258577B (en:Method) |
| MX (1) | MX376824B (en:Method) |
| PE (1) | PE20181197A1 (en:Method) |
| SG (1) | SG10201908839QA (en:Method) |
| TW (1) | TW201720796A (en:Method) |
| UY (1) | UY36949A (en:Method) |
| WO (1) | WO2017066402A1 (en:Method) |
| ZA (1) | ZA201802451B (en:Method) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20200690T1 (hr) | 2015-05-20 | 2020-07-24 | Amgen Inc. | Agonisti triazola apj receptora |
| EP3530660A1 (en) | 2015-06-03 | 2019-08-28 | Bristol-Myers Squibb Company | 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders |
| CN108473466B (zh) | 2015-12-04 | 2022-04-19 | 百时美施贵宝公司 | 爱帕琳肽受体激动剂及使用方法 |
| MX380669B (es) | 2015-12-16 | 2025-03-12 | Bristol Myers Squibb Co | Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj). |
| SG11201808163WA (en) | 2016-03-24 | 2018-10-30 | Bristol Myers Squibb Co | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists |
| US9988369B2 (en) | 2016-05-03 | 2018-06-05 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the APJ receptor |
| EP3468956B1 (en) | 2016-06-14 | 2021-03-03 | Bristol-Myers Squibb Company | 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-ones as apj agonists |
| KR102521955B1 (ko) * | 2016-06-14 | 2023-04-13 | 브리스톨-마이어스 스큅 컴퍼니 | Apj 수용체 효능제로서의 4-히드록시-3-술포닐피리딘-2(1h)-온 |
| ES2820223T3 (es) * | 2016-10-14 | 2021-04-20 | Bristol Myers Squibb Co | Agonistas de APJ de 3-sulfonil-5-aminopiridin-2,4-diol |
| WO2018093580A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
| WO2018093576A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the apj receptor |
| WO2018097945A1 (en) | 2016-11-16 | 2018-05-31 | Amgen Inc. | Heteroaryl-substituted triazoles as apj receptor agonists |
| US10736883B2 (en) | 2016-11-16 | 2020-08-11 | Amgen Inc. | Triazole furan compounds as agonists of the APJ receptor |
| MA46827A (fr) | 2016-11-16 | 2019-09-25 | Amgen Inc | Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj |
| EP3541810B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole phenyl compounds as agonists of the apj receptor |
| MA50509A (fr) | 2017-11-03 | 2021-06-02 | Amgen Inc | Agonistes de triazole fusionnés du récepteur apj |
| WO2019213006A1 (en) | 2018-05-01 | 2019-11-07 | Amgen Inc. | Substituted pyrimidinones as agonists of the apj receptor |
| WO2025153720A1 (en) * | 2024-01-19 | 2025-07-24 | Scenic Biotech Bv | Pla2g15 inhibitors |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH602664A5 (en) | 1973-06-14 | 1978-07-31 | Sandoz Ag | 2-Tert. amino-alkylamino-pyrimidine derivs. |
| ZA835878B (en) * | 1982-08-23 | 1985-03-27 | Warner Lambert Co | Cardiotonic agents |
| GB2263639A (en) | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substituted pyrimidinones as neurotensin antagonists |
| DE4425616A1 (de) * | 1994-07-20 | 1996-01-25 | Basf Ag | Hydroxypyridoncarbonsäureamide, deren Herstellung und Verwendung |
| US5985884A (en) | 1996-07-01 | 1999-11-16 | Dr. Reddy's Research Foundation | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
| JP2004504302A (ja) | 2000-07-18 | 2004-02-12 | ニューロジェン・コーポレーション | ５−置換２−アリール−４−ピリミジノン |
| TW200300349A (en) | 2001-11-19 | 2003-06-01 | Sankyo Co | A 4-oxoqinoline derivative |
| KR20050036911A (ko) | 2002-05-09 | 2005-04-20 | 싸이토키네틱스, 인코포레이티드 | 화합물들, 방법 및 조성물 |
| WO2003099211A2 (en) | 2002-05-23 | 2003-12-04 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| JP2004339159A (ja) | 2003-05-16 | 2004-12-02 | Sankyo Co Ltd | ４−オキソキノリン誘導体を含有する医薬組成物 |
| EP1699777B1 (en) | 2003-09-08 | 2012-12-12 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| EP1682534A2 (en) | 2003-11-03 | 2006-07-26 | Cytokinetics, Inc. | Pyrimidin-4-one compounds, compositions, and methods |
| US7625912B2 (en) | 2003-12-19 | 2009-12-01 | Merck & Co. Inc | Mitotic kinesin inhibitors |
| WO2007033196A1 (en) | 2005-09-14 | 2007-03-22 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| WO2007037543A1 (ja) | 2005-09-29 | 2007-04-05 | Banyu Pharmaceutical Co., Ltd. | ビアリールアミド誘導体 |
| CA2630884A1 (en) | 2005-11-30 | 2007-06-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-met and uses thereof |
| EP2016056A4 (en) | 2006-04-21 | 2010-11-10 | Univ Boston | IONIC VISCOELASTIC AND VISCOELASTIC SALTS |
| JP2007308441A (ja) * | 2006-05-22 | 2007-11-29 | Sumitomo Chemical Co Ltd | 含複素環化合物及びその用途 |
| ES2527722T3 (es) | 2006-10-10 | 2015-01-28 | Proionic Gmbh & Co Kg | Método para reaccionar 2-carboxilatos 1,3-heteroaromáticos con agua |
| WO2008052861A2 (de) | 2006-10-10 | 2008-05-08 | Proionic Production Of Ionic Substances Gmbh & Co Keg | Verfahren zur herstellung von 1,3 -hetero-aromatischen carbonaten |
| CL2008000065A1 (es) | 2007-01-12 | 2008-09-22 | Smithkline Beecham Corp | Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia. |
| US8314087B2 (en) | 2007-02-16 | 2012-11-20 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and methods of use |
| EP3042660A3 (en) | 2008-04-15 | 2016-10-26 | RFS Pharma, LLC. | Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections |
| WO2010072696A2 (de) | 2008-12-22 | 2010-07-01 | Basf Se | Mischungen hydrophober und hydrophiler ionischer flüssigkeiten und ihre verwendung in flüssigkeitsringverdichtern |
| CA2762680C (en) | 2009-05-21 | 2018-04-17 | Chlorion Pharma, Inc. | Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics |
| EP2604260B1 (en) | 2010-08-10 | 2017-05-10 | Shionogi&Co., Ltd. | Novel heterocyclic derivatives and pharmaceutical composition containing same |
| EP2715858A1 (en) | 2011-05-31 | 2014-04-09 | Merck Patent GmbH | Electrolyte formulations |
| KR20140034256A (ko) | 2011-05-31 | 2014-03-19 | 메르크 파텐트 게엠베하 | 히드리도-트리시아노-보레이트 음이온을 포함하는 화합물 |
| US20140005181A1 (en) * | 2012-06-21 | 2014-01-02 | Sanford-Burnham Medical Research Institute | Small molecule antagonists of the apelin receptor for the treatment of disease |
| WO2014004676A1 (en) | 2012-06-26 | 2014-01-03 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors as neuroprotective agents in the cns |
| AU2013320323B2 (en) * | 2012-09-21 | 2018-03-15 | Sanofi | Benzoimidazole-carboxylic acid amide derivatives as APJ receptor modulators |
| DE102012021452A1 (de) | 2012-10-31 | 2014-04-30 | Merck Patent Gmbh | Salze mit Trihydroperfluoralkoxybutansulfonat- oder Trihydroperfluoralkoxypropansulfonat-Anion |
| US9670162B2 (en) | 2013-03-14 | 2017-06-06 | The Board Of Trustees Of The Leland Stanford Junio | Mitochondrial aldehyde dehyrogenase-2 modulators and methods of use thereof |
| WO2014207100A1 (en) | 2013-06-27 | 2014-12-31 | Basf Se | A process for coating paper with cellulose using a solution containing cellulose |
| HUE062265T2 (hu) | 2013-06-27 | 2023-10-28 | Pfizer | Heteroaromás vegyületek és azok alkalmazása dopamin D1 ligandumokként |
| JP6483124B2 (ja) | 2013-11-29 | 2019-03-13 | プロイオニック ゲーエムベーハー | マイクロ波照射を使用した接着剤の硬化方法 |
| WO2015184011A2 (en) | 2014-05-28 | 2015-12-03 | Sanford-Burnham Medical Research Institute | Agonists of the apelin receptor and methods of use thereof |
| MA39999A (fr) * | 2014-06-06 | 2015-12-10 | Res Triangle Inst | Agonistes du récepteur de l'apeline (apj) et leurs utilisations |
| WO2016074757A1 (de) | 2014-11-11 | 2016-05-19 | Merck Patent Gmbh | Verfahren zur herstellung von mono- und bis(perfluoralkyl)fluorophosphatsalzen und deren säuren |
| RU2683245C1 (ru) | 2015-04-24 | 2019-03-27 | Сионоги Энд Ко., Лтд. | 6-членные гетероциклические производные и содержащая их фармацевтическая композиция |
| HRP20200690T1 (hr) | 2015-05-20 | 2020-07-24 | Amgen Inc. | Agonisti triazola apj receptora |
| EP3530660A1 (en) | 2015-06-03 | 2019-08-28 | Bristol-Myers Squibb Company | 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders |
| KR101711744B1 (ko) | 2015-07-16 | 2017-03-02 | 경희대학교 산학협력단 | 옥사디아졸 유도체, 이의 제조방법 및 이를 포함하는 전자수송층 |
| WO2017091513A1 (en) | 2015-11-24 | 2017-06-01 | Daiichi Sankyo Company, Limited | Novel azole derivatives as apelin receptor agonist |
| CN108473466B (zh) | 2015-12-04 | 2022-04-19 | 百时美施贵宝公司 | 爱帕琳肽受体激动剂及使用方法 |
| MX380669B (es) | 2015-12-16 | 2025-03-12 | Bristol Myers Squibb Co | Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj). |
| SG11201808163WA (en) | 2016-03-24 | 2018-10-30 | Bristol Myers Squibb Co | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists |
| EP3468956B1 (en) | 2016-06-14 | 2021-03-03 | Bristol-Myers Squibb Company | 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-ones as apj agonists |
| KR102521955B1 (ko) | 2016-06-14 | 2023-04-13 | 브리스톨-마이어스 스큅 컴퍼니 | Apj 수용체 효능제로서의 4-히드록시-3-술포닐피리딘-2(1h)-온 |
| ES2820223T3 (es) | 2016-10-14 | 2021-04-20 | Bristol Myers Squibb Co | Agonistas de APJ de 3-sulfonil-5-aminopiridin-2,4-diol |
-
2016
- 2016-10-13 ES ES16784732T patent/ES2774945T3/es active Active
- 2016-10-13 MX MX2018004344A patent/MX376824B/es active IP Right Grant
- 2016-10-13 CA CA3001974A patent/CA3001974A1/en not_active Abandoned
- 2016-10-13 EP EP16784732.6A patent/EP3362442B1/en active Active
- 2016-10-13 SG SG10201908839Q patent/SG10201908839QA/en unknown
- 2016-10-13 TW TW105133123A patent/TW201720796A/zh unknown
- 2016-10-13 CN CN201680072835.5A patent/CN108368087B/zh active Active
- 2016-10-13 KR KR1020187013119A patent/KR102707502B1/ko active Active
- 2016-10-13 JP JP2018519425A patent/JP6837482B2/ja active Active
- 2016-10-13 BR BR112018007395A patent/BR112018007395A2/pt not_active IP Right Cessation
- 2016-10-13 PE PE2018000536A patent/PE20181197A1/es unknown
- 2016-10-13 AU AU2016340264A patent/AU2016340264B2/en not_active Ceased
- 2016-10-13 US US15/767,364 patent/US10392347B2/en active Active
- 2016-10-13 EA EA201890858A patent/EA034857B1/ru not_active IP Right Cessation
- 2016-10-13 UY UY0001036949A patent/UY36949A/es unknown
- 2016-10-13 WO PCT/US2016/056769 patent/WO2017066402A1/en not_active Ceased
-
2018
- 2018-04-09 IL IL258577A patent/IL258577B/en active IP Right Grant
- 2018-04-13 ZA ZA2018/02451A patent/ZA201802451B/en unknown
- 2018-04-13 CL CL2018000953A patent/CL2018000953A1/es unknown
- 2018-05-10 CO CONC2018/0004968A patent/CO2018004968A2/es unknown
Non-Patent Citations (1)
| Title |
|---|
| CAO JIANGANG ET AL, "Targeting Drugs to APJ Receptor: The Prospect of Treatment of Hypertension and Other Cardiovascular Diseases", CURRENT DRUG TARGETS, (2015-02-01), vol. 16, no. 2, ISSN 1389-4501, pages 148 - 155 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20180297954A1 (en) | 2018-10-18 |
| JP6837482B2 (ja) | 2021-03-03 |
| EA201890858A1 (ru) | 2018-09-28 |
| KR102707502B1 (ko) | 2024-09-13 |
| WO2017066402A1 (en) | 2017-04-20 |
| CL2018000953A1 (es) | 2018-08-24 |
| IL258577B (en) | 2020-07-30 |
| AU2016340264A1 (en) | 2018-05-31 |
| KR20180067599A (ko) | 2018-06-20 |
| UY36949A (es) | 2017-04-28 |
| PE20181197A1 (es) | 2018-07-23 |
| EP3362442B1 (en) | 2020-01-29 |
| BR112018007395A2 (pt) | 2018-10-23 |
| US10392347B2 (en) | 2019-08-27 |
| EA034857B1 (ru) | 2020-03-30 |
| EP3362442A1 (en) | 2018-08-22 |
| JP2018530591A (ja) | 2018-10-18 |
| CA3001974A1 (en) | 2017-04-20 |
| CO2018004968A2 (es) | 2018-10-10 |
| ES2774945T3 (es) | 2020-07-23 |
| SG10201908839QA (en) | 2019-10-30 |
| CN108368087B (zh) | 2022-04-12 |
| CN108368087A (zh) | 2018-08-03 |
| MX376824B (es) | 2025-03-07 |
| ZA201802451B (en) | 2020-01-29 |
| IL258577A (en) | 2018-05-31 |
| MX2018004344A (es) | 2018-05-01 |
| TW201720796A (zh) | 2017-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016340264B2 (en) | 2,4-dihydroxy-nicotinamides as APJ agonists | |
| AU2016270903B2 (en) | 4-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonists for use in the treatment of cardiovascular disorders | |
| KR102384668B1 (ko) | Apj 효능제로서의 6-히드록시-5-(페닐/헤테로아릴술포닐)피리미딘-4(1h)-온 | |
| EP3433247B1 (en) | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists | |
| EP3383860B1 (en) | Apelin receptor agonists and methods of use | |
| AU2016372048B2 (en) | Heteroarylhydroxypyrimidinones as agonists of the APJ receptor | |
| EP3468952A1 (en) | 4-hydroxy-3-sulfonylpyridin-2(1h)-ones as apj receptor agonists | |
| WO2018071622A1 (en) | 3-sulfonyl-5-aminopyridine-2,4-diol apj agonists | |
| NZ786241A (en) | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |